While a guest on the "Club Shay Shay" podcast, Iglesias explained why he ditched the GLP-1 that seemed to be working: "The problem with Ozempic is you're going to lose more muscle than fat." A 2024 review in Diabetes, Obesity, and Metabolism supports his assertion to an extent, stating that studies show GLP-1 use may cause the loss of up to 60% of a person's total lean muscle
Bottom line: The combination is the standard backbone for T2D care in 2026 FAQ Will I Lose More Weight on Both Than on Semaglutide Alone
Therefore, endogenous GIP seems to retain a role in postprandial glucose regulation following gastric sleeve but when the first part of the small intestine is bypassed (Roux-en-Y gastric bypass) endogenous GIP does not contribute to the postprandial glucose regulation (79)
26 Through mediating the post-translational modification dependent on NAD + , sirtuins modulate the adaptation to the altered cellular energetic status, especially the activation of oxidative metabolism and stress resistance in mitochondria in various physiological or pathological conditions
Similarly, 21% of patients with MASLD and diabetes/obesity began GLP-1 therapy within six months, again outpacing those without the comorbidity
Oral GLP-1 formulations with better bioavailability are in development
